Earlier this month, the House of Representatives passed the 21st Century Cures Act in a rare bi-partisan effort. The bill is meant to speed the development of lifesaving treatments, but critics warn it may also allow ineffective or even harmful drugs onto the market.
The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.
- Dr. Jerry Avorn author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
- Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
- Marc Kaufman reporter on the national desk of "The Washington Post"
- Alan Goldhammer, PhD associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
- Dr. Sandra Kweder deputy director of the FDA's Office of New Drugs
Most Recent Shows
Secretly-recorded videos have reopened the fight over federal funding for Planned Parenthood. We examine new hurdles for the organization, the political response and the latest in the battle over abortion rights in the U.S.
A novel about Vivian, a young Irish girl sent by rail from a New York City tenement to Minnesota in the early 1900s. She was one of thousands of abandoned children sent to live with rural families for a better life. But not all ended up in loving homes.
An estimated 11 million Americans could see their disability benefits slashed next year if Congress fails to take action. The White House and Republican lawmakers have opposing solutions. Social Security's disability fund and how to keep the program solvent.